

**REMARKS**

Claims 1-13 are pending in the application. Claims 1-13 were subject to the Requirement for Restriction.

**Restriction Requirement**

The Examiner has required restriction to one of the following inventions under 35 U.S.C. §§ 121 and 372:

- Group 1: Claims 1-4, drawn to a methods for diagnosing inflammatory disease;
- Group 2: Claims 5-9, drawn to oligonucleotides and kits comprising oligonucleotides;
- Group 3: Claim 10, drawn to a method for analyzing galectin-2 gene expression;
- Group 4: Claims 11-12, drawn to methods for screening for a therapeutic agent comprising analyzing gene expression; and
- Group 5: Claim 13, drawn to a method for screening for a therapeutic agent comprising assaying binding to a gene product.

**Election with Traverse**

In order to be responsive to the requirement for restriction, Applicants elect the invention set forth in Group 1 as “oligonucleotides and kits comprising oligonucleotides”, with *traverse*. Applicants submit that at least Claims 1-4 read on the elected invention.

**Traverse**

Notwithstanding the election of the invention set forth in Group 1 as “oligonucleotides and kits comprising oligonucleotides” in order to be responsive to the Restriction Requirement, Applicants respectfully traverse the Examiner’s requirement for restriction.

The Examiner has stated that the groups of inventions set forth in the Restriction Requirement do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they allegedly lack the same or corresponding special technical feature. In particular, the Office states that the technical feature shared in common by the groups appears to be the galectin-2 gene, and further that GenBank Accession AL022215 (June 5, 2003) teaches a portion of human chromosome which contains the galectin-2 gene.

In response, Applicants submit that the claims encompass a special technical feature which defines a contribution over GenBank Accession AL022215. However, even if the Examiner’s characterization of Groups 1-5 were to be considered correct, Applicants respectfully request that at least the inventions defined in claims 1-9 be examined in the instant application, pursuant to the guidelines set forth in M.P.E.P. § 803. That is, the Examiner is respectfully requested to reconsider the requirement and find that there would not appear to be a “serious burden” on the Patent and Trademark Office in examining claims directed to the non-elected invention.


In particular, it would appear that a search for the inventions identified by the Examiner would significantly overlap. That is, if the Examiner were to perform a search for the invention of Group 1, there would not appear to be a serious burden in continuing the examination of Group 2. Furthermore, the Examiner has not stated that examination of all

the claims would pose a burden, much less set forth any reasons why examination of the all the restricted groups would be burdensome. For this reason, and consistent with the Office policy as set forth in M.P.E.P. § 803, Applicants respectfully request that the Examiner reconsider and withdraw the Requirement for Restriction.

In view of the foregoing, it is respectfully requested that the Examiner reconsider the Requirement for Restriction, and withdraw the same so as to give an examination on the merits on all of the claims pending in this application, for which Applicants have timely paid appropriate claim fees.

Should the Examiner have any questions, the Examiner is invited to contact the undersigned at the below-listed telephone number.

Respectfully submitted,  
Toshihiro TANAKA et al.

  
Bruce H. Bernstein  
Reg. No. 29,027 42,920

October 7, 2008  
GREENBLUM & BERNSTEIN, P.L.C.  
1950 Roland Clarke Place  
Reston, VA 20191  
(703) 716-1191